Edinburgh-based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumour
Amy Brown from BiotechTV interviewed our CEO Ken Macnamara at our offices, where he discussed our breakthrough Synthetic Super-Enhancer (SSE) platform, Odysseus, and our unique ‘Trojan Horse’ approach for treating aggressive cancers, along with our compelling preclinical data.